Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HRS-5635 injection in virally suppressed HBeAg-negative chronic hepatitis B previously treated with nucleos(t)ide analogues
CTR20261991Phase 3Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jul 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-5635 in Chronic Hepatitis B (CHB), sponsored by Fujian Shengdi Pharmaceuticals. Started Jul 2026; status: active.
02
Drugs
HRS-5635
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20261991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261991.